Target intelligence / Profile preview

Myosin-binding protein C, fast-type (MYBPC2)

Target
MYBPC2
Molecular classification
Structural protein, Sarcomeric protein, Other
01

Overview

Myosin-binding protein C, fast-type (MYBPC2) is an accessory component of the thick filament in vertebrate striated muscle, specifically enriched in fast skeletal muscle. It is part of the myosin-binding protein C family, which comprises fast-, slow-, and cardiac-type isoforms, each encoded by separate genes. MYBPC2 localizes to the cross-bridge-bearing C region of the A-band and is fundamental for proper sarcomeric architecture, modulating the speed, force, and calcium sensitivity of muscle contraction. The protein engages in specific protein-protein interactions through conserved modular domains, binding both myosin (particularly subfragment 2) and actin, and thereby subtends both structural and regulatory roles within the sarcomere. Genetic mutations in MYBPC2 can result in skeletal myopathies such as distal arthrogryposis, and its absence leads to defective contractile function and compromised muscle regeneration and integrity[2][4][5][6]. Unlike its cardiac and slow skeletal counterparts, MYBPC2 (fast skeletal MyBP-C) is not currently targeted by drugs and is not a known direct therapeutic target.

Other names
MYBPCFFast MyBP-CfsMyBP-CC-protein (skeletal muscle fast isoform)fast skeletal-type muscle myosin-binding protein-Cfast-type muscle myosin-binding-protein Cmyosin binding protein C, fast typetesticular tissue protein Li 126MGC163408
02

Biological functions

Regulation of muscle contractionMaintenance of sarcomeric structureModulation of myosin-actin interactionRegulation of calcium sensitivity in muscle fibers
03

Disease associations

Congenital myopathy (e.g., distal arthrogryposis)Muscle weakness disordersOther
04

Safety considerations

Not a therapeutic target; genetic deficiency associated with muscle structure and function impairmentPotential pathogenicity in congenital myopathies when mutated or deleted
05

Biomarkers

MYBPC2 mutation as a genetic biomarker for distal arthrogryposisLoss of MYBPC2 protein as a marker of skeletal muscle disease

Beyond the preview

Go deeper on Myosin-binding protein C, fast-type (MYBPC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myosin-binding protein C, fast-type (MYBPC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call